BrainStorm Cell Therapeutics Inc.
Tel Aviv
425 articles about BrainStorm Cell Therapeutics Inc.
-
BrainStorm Cell Therapeutics Announces Full Year 2021 Financial Results and Provides a Corporate Update
3/28/2022
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the financial results for the fiscal year ended December 31, 2021 and provided a corporate update.
-
It was a busy week for clinical trial announcements. Here's a look.
-
BrainStorm Cell Therapeutics’ NurOwn has taken the amyotrophic lateral sclerosis (ALS) community by storm with new genetic data from its Phase III trial.
-
BrainStorm to Announce Fourth Quarter and Fiscal Year 2021 Financial Results and Provide a Corporate Update
3/14/2022
BrainStorm Cell Therapeutics Inc. announced that the Company will hold a conference call to update shareholders on financial results for the fourth quarter and year ended December 31, 2021, and provide a corporate update, at 8:00 a.m. Eastern Time on Monday, March 28, 2022.
-
BrainStorm Cell Therapeutics Abstract Selected as Late-Breaking Presentation at the 2022 MDA Clinical & Scientific Conference
2/28/2022
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the acceptance of a scientific abstract as a late-breaking oral presentation at the 2022 MDA (Muscular Dystrophy Association) Clinical & Scientific Conference.
-
Brainstorm Cell Therapeutics Announces Grant of a New Brazilian Patent Covering Methods of Manufacturing NurOwn®
2/15/2022
Brainstorm Cell Therapeutics Inc. today announced that the Brazilian Patent Office has granted the patent application.
-
BrainStorm Cell Therapeutics to Present at the 12th Annual California ALS Research Summit
1/27/2022
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Kern, M.D., MHSc, President and Chief Medical Officer of BrainStorm Cell Therapeutics, will provide a corporate and clinical overview at the 12th Annual California ALS Research Summit.
-
BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2022
1/4/2022
BrainStorm Cell Therapeutics Inc. announced that Ralph Kern, M.D. MHSc, President and Chief Medical Officer of Brainstorm Cell Therapeutics, will provide a corporate and clinical overview at Biotech Showcase™ 2022, to be held virtually January 10-12 and 17-18, 2022.
-
From the continuing fight against COVID-19 to new companies emerging in exciting therapeutic areas to the people who mattered most, here’s a look at just some of the biggest successes, most dramatic flops – and a few that fall somewhere in between.
-
FDA Authorizes Further NurOwn® Dosing Under Expanded Access Program
12/27/2021
BrainStorm Cell Therapeutics Inc. today announced plans for a dosing extension of NurOwn® for participants who completed the Expanded Access Protocol (EAP).
-
BrainStorm Cell Therapeutics Announces peer reviewed publication of NurOwn's® Phase 3 Study for ALS in Muscle and Nerve
12/13/2021
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the peer reviewed publication of Phase 3 clinical data in Muscle and Nerve.
-
BrainStorm Cell Therapeutics is making a strong comeback after the FDA was a little impressed with Phase III results of amyotrophic lateral sclerosis treatment.
-
A U.S. Congress subcommittee unanimously approved the ACT for ALS bill in a decision that could soon pour massive funding into the search for treatment for this debilitating and deadly disease.
-
BrainStorm Cell Therapeutics and Catalent Announce Completion of Technology Transfer for NurOwn® Manufacturing
12/7/2021
BrainStorm Cell Therapeutics Inc. and Catalent today announced that the technology transfer for NurOwn® manufacturing at Catalent's facility has been finalized.
-
BrainStorm Cell Therapeutics to Present New Biomarker Data on NurOwn® at the International Symposium on ALS/MND
12/2/2021
BrainStorm Cell Therapeutics Inc. today announced that biomarker data on NurOwn® will be presented at the 32nd International Symposium on ALS/MND, to be held virtually 7-10 December 2021.
-
BrainStorm Cell Therapeutics Announces the Presentation of New Analyses from the Phase 3 Trial of NurOwn® in ALS at the 4th Annual ALS ONE Research Symposium
11/29/2021
BrainStorm Cell Therapeutics Inc. today announced the presentation of new analyses from the Phase 3 trial of NurOwn at the 4th Annual ALS ONE Research Symposium.
-
BrainStorm Cell Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
11/15/2021
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced financial results for the quarter ended September 30, 2021, and provided a corporate update.
-
BioSpace Movers & Shakers, Nov. 12
11/12/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs
11/8/2021
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced executive appointments as the company prepares for future growth.
-
Brainstorm Cell Therapeutics Announces Appointment of Menghis Bairu, MD, to Board of Directors
10/28/2021
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced the appointment of Menghis Bairu, MD, to the company's Board of Directors.